CMA “ignored” evidence in excessive pricing case, Pfizer says
The UK’s Competition and Markets Authority “ignored” evidence in its decision that two drug companies’ prices were excessive, their defence counsel have argued.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.